- Home
- NG vs CDNA Comparison
NG vs CDNA Comparison
Compare NG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- CDNA
- Stock Information
- Founded
- NG 1984
- CDNA 1998
- Country
- NG Canada
- CDNA United States
- Employees
- NG N/A
- CDNA N/A
- Industry
- NG Precious Metals
- CDNA Medical Specialities
- Sector
- NG Basic Materials
- CDNA Health Care
- Exchange
- NG Nasdaq
- CDNA Nasdaq
- Market Cap
- NG 940.4M
- CDNA 1.0B
- IPO Year
- NG N/A
- CDNA 2014
- Fundamental
- Price
- NG $3.80
- CDNA $15.36
- Analyst Decision
- NG
- CDNA Buy
- Analyst Count
- NG 0
- CDNA 7
- Target Price
- NG N/A
- CDNA $30.33
- AVG Volume (30 Days)
- NG 6.4M
- CDNA 1.1M
- Earning Date
- NG 06-25-2025
- CDNA 04-30-2025
- Dividend Yield
- NG N/A
- CDNA N/A
- EPS Growth
- NG N/A
- CDNA N/A
- EPS
- NG N/A
- CDNA 1.07
- Revenue
- NG N/A
- CDNA $346,421,000.00
- Revenue This Year
- NG N/A
- CDNA $13.28
- Revenue Next Year
- NG N/A
- CDNA $15.13
- P/E Ratio
- NG N/A
- CDNA $14.36
- Revenue Growth
- NG N/A
- CDNA 25.92
- 52 Week Low
- NG $2.26
- CDNA $7.42
- 52 Week High
- NG $5.06
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- NG 51.62
- CDNA 38.73
- Support Level
- NG $3.72
- CDNA $14.09
- Resistance Level
- NG $4.29
- CDNA $18.71
- Average True Range (ATR)
- NG 0.41
- CDNA 1.03
- MACD
- NG -0.06
- CDNA -0.18
- Stochastic Oscillator
- NG 28.41
- CDNA 23.48
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.